Going into STS pali data, there is one thing that makes this different than any other binary events. If Picasso 3 is successful, then Ziopharm has data lined up for pali in SCLC and other cancers that could make the drug exponentially more valuable. These data will bolster the value of the drug with positive STS data, and will serve as a safety net if the STS trial fails (perhaps it doesn't work in STS but will work in SCLC or other cancers). Regardless of how pali turns out, there is a rapidly maturing pipeline of synthetic DNA drugs that could revolutionize the oncology field as we know it.
Taking all this into account, this is the kind of binary event you want to get involved in. Positive data will send the stock north of $7, and in my opinion, that will just be the beginning as data from these other pali indications mature. If the data is negative, it's going to hurt in the near-term, but in the long run with the synthetic pipeline, it's very unlikely that all is lost.
I have been around ZIOP many years now...excited to finally see in a matter of weeks exactly how bright Ziopharm's future looks!
Agree in part disagree in part...sure it's a bit different than a one show pony but their advanced pipeline is Pali heavy, so if this one fails the others are in trouble. So big ups for good results but if not then this goes back to being purely speculative. So really then, it's not that different.
And I forgot to mention the whole point of all that: don't sell on positive Picasso 3 data! Shorts will be trapped and nothing but positive news will follow with ASCO coming up, partnering, and several follow on indications.